*Facility ID # : __________*Event # : __________ *Patient ID # : _____________ Social Security # : ___ ___ ___ - ___ ___ - ___ ___ ___ ___ Secondary ID.

Slides:



Advertisements
Similar presentations
PART II CATHETER RELATED BLOOD STREAM INFECTION (CR-BSI) CATHETER RELATED URINARY TRACT INFECTIN (CR-UTI)
Advertisements

TREATMENT FOR SUPERIMPOSED PSEUDOMONAS AERUGINOSA INFECTION.
Facility ID:________________Event#_________________________ *Patient ID:_____________________ Social Security#: __ __ __ - __ __ - __ __ __ __ Secondary.
Edward L. Goodman, MD Core Faculty Hospital Epidemiologist June 27, 2013.
Antibiotics.
Introduction to the National Healthcare Safety Network (NHSN) Richard Rodriguez, MPH Connecticut Department of Public Health 4/9/2014 Thank you to CDC.
Community-acquired bacterial infections. The most frequent etiologic agents of bacterial tonsillitis and tonsillopharyngitis are Streptococcus pyogenes.
Enoch Omonge University of Nairobi
MANUAL on ALERT ORGANISM SURVEILLANCE
Plate 1a: Staphylococcus aureus resistant to penicillin (P0.5) only. Note the annular radius of the zone of inhibition of 9.5 mm around the cefoxitin (FOX.
Sorting Out Antibiotics: A systematic approach to antibiotic selection Kenneth Alexander, M.D., Ph.D. Associate Professor of Pediatrics and Microbiology.
Gram-positive bacteria: Staphylococci
Content Management Portal PRA Disclosure Statement According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection.
Empiric Treatment: Pneumonia. Overview of Pneumonia diseases.asp?did=38http://
COL Helen Viscount, PhD, D(ABMM) LTC Steven Mahlen, PhD, D(ABMM)
Culture and Sensitivity Helping the Infection Preventionist Interpret Antibiograms Walter Phillips, BS, MS, PhD Director of Microbiology TriStar Healthcare.
Facility ID#: *HCW ID#:Social Security #: Secondary ID#: HCW Name, Last: First: Middle: Street Address: City:State:Zip Code: Home Phone: ( ) Address:
Antibiotics 101 Puja Van Epps 1/20/14.
Train-the-Trainer Understanding multidrug-resistance: Focus on Carbapenems Customize this presentation with your organization’s logo, etc. 13/17/2014.
MDR Organisms in Holy Family Hospital Rawalpindi
Methods Revised Abstract Methods Results TP-271 is a Potent, Broad-Spectrum Fluorocycline with Activity Against Community-Acquired Bacterial Respiratory.
Custom Event Page 1 of 4 * required for saving Facility ID: Event #: *Patient ID:Social Security #: Secondary ID: Patient Name, Last: First: Middle: *Gender:
Do Physicians Find Our AST Reports As Confusing As We Do? Louis B. Rice, M.D. Louis Stokes Cleveland VA Medical Center and Case Western Reserve University.
Mary Andrus, BA, RN, CIC Division of Healthcare Quality Promotion
Zunilda Djanun*, Rudyanto S**, Yulia Rosa***, *Dept. Clinical Pharmacology FMUI/CMH, **ICU CMH, *** Dept. Clinical Microbiology FMUI.
Facility ID: Vaccination #: Healthcare Worker Demographics *HCW ID#: HCW Name, Last:First:Middle: *Gender:  F  M *Date of Birth: *Work Location: *Occupation:
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training.
Antimicrobial Resistance patterns among nosocomial gram negative bacilli by E-test and disc diffusion methods in Sina and Imam Hospital.
김의종(집필대표), 강정옥, 김미나, 김민중, 김성일, 이경원, 이도현, 이장호, 이남용, 이창규, 신종희, 장철훈, 최혜심
Common ID Syndromes March 2014.
Listing Antimicrobial Resistant Pathogens of Public Health Importance Implications for Drug Development Listing Antimicrobial Resistant Pathogens of Public.
Figure 1 shows the 10 most frequently isolated blood pathogens in these hospitals from 1997 through These species represent about 85% of blood isolates.
Antibiotics 101 A review of common infections and their treatment For others, like me, who have a mental block against all things related to antibiotics.
Impetigo The best topical agent is mupirocin; other agents, such as bacitracin and neomycin, are less effective. Patients who have numerous lesions or.
Hospital Acquired Pneumonia(HAP): is defined as a pneumonia which occurs after 48 hours of admission to hospital. Hospital Acquired Pneumonia(HAP): is.
EARS-Net data on Antimicrobial Resistance in Ireland, Q3 2015
Center for Drug Evaluation and Research March 6, 2005 Bacteremia and Endocarditis: Products and Guidance Janice Soreth, MD Director Division of Anti-Infective.
CLINICAL PHARMACOLOGY OF ANTIBACTERIAL AND ANTIVIRAL AGENTS
Facility ID:Event #: *Patient ID:Social Security #: Secondary ID: Patient Name, Last: First: Middle: *Gender: F M*Date of Birth: Ethnicity (specify):Race.
N.meningitidis Ceftriaxone- children and adults Cefotaxime- neonates Ampicillin Chloramphenicol N. gonorrhea Ceftriaxone Cefotaxime Ciprofloxacin Spectinomycin.
Dr. Laila M. Matalqah Ph.D. Pharmacology
Guideline for the Diagnosis and Management of Adults in LTC with Urinary Tract Infection (Part 2) This is intended as a guide for evidence-based decision-making.
*Facility ID:*Event #: *Patient ID:Social Security #: Secondary ID: Patient Name, Last: First: Middle: *Gender: F M*Date of Birth: Ethnicity (specify):Race.
* required for saving Tracking #: Facility ID:*Survey Year: Facility Characteristics *Ownership (check one): □ For profit □ Not for profit, including church.
*Facility ID # : _____________ *HCW ID # : _____________ Social Security # : ___ ___ ___ - ___ ___ - ___ ___ ___ ___ Secondary ID # : _____________ HCW.
Purposes of NHSN Participation in the NHSN reflects the individual facility’s need for high quality and timely data on adverse events and adherence to.
Urinary Tract Infection (UTI) for LTCF Page 1 of 4 OMB No. xxxx-xxxx Exp. Date: xx-xx-xxxx * required for saving *Facility ID: Event #: *Resident ID:*Social.
National Hospital Care Survey (NHCS). 2 Overview What is the National Center for Health Statistics (NCHS)? What is the National Hospital Care Survey (NHCS)?
Facility ID#: Med Admin#: Healthcare Worker Demographics *HCW ID#: *HCW Name, Last:First:Middle: *Gender:  F  M  Other *Date of Birth:// *Work Location:*Occupation:
A.Facility Information: Facility ID: __________ 1.Ownership of your dialysis center (choose one): ____For profit ____Not for profit ____Government 2. Location.
The Alien Flight Student Program AFSP An overview of the applications that encompass the AFSP Program COPYRIGHT AND GOVERNMENT PURPOSE RIGHTS NOTICE Copyright.
Evidence-Based Practice Working Group Focus Group Guide NCCCP Experiences with Using/Implementing the Template for Community Outreach (TCO) Brenda Adjei,
Using Nursing Home Antibiograms To Improve Antibiotic Prescribing and Delivery Training Slides for Nursing Home Nurses Comprehensive Antibiogram Toolkit.
Assurance of Confidentiality: The information obtained in this surveillance system that would permit identification of any individual or institution is.
National Hospital Care Survey (NHCS) Acute Coronary Syndrome Study.
Thank you very much for including the HD*Calc software ( on your website or social media platform. The National Cancer Institute.
*Facility ID:*Event #: *Patient ID:Social Security #: Secondary ID: Patient Name, Last: First: Middle: *Gender: F M Other *Date of Birth: Ethnicity (specify):Race.
Facility ID:Procedure #: *Patient ID:Social Security #: Secondary ID: Patient Name, Last: First: Middle: *Gender: F M*Date of Birth: Ethnicity (specify):Race.
OMB Control No , Expires on: 11/30/2014.
Principles of Medical Science Pharmacology Review
Facility Information: *Facility Name: __________________________________________________________________ *Main Telephone Number: ( ) ______-____________.
Afaq R. Afridi, Tanveer Ahmad, Arshad Hussain and Abdul Samad.
EARS-Net data on Antimicrobial Resistance in Ireland, Q
International Journal of Infectious Diseases
The Role of the Microbiology Laboratory in AMS programs
Average susceptibility
Antibiotics sensitivity of microorganism causing nosocomial infections
19/ژانويه/17
Human health risks associated with antimicrobial-resistant enterococci and Staphylococcus aureus on poultry meat  V. Bortolaia, C. Espinosa-Gongora, L.
Empiric antibiotic therapy
Presentation transcript:

*Facility ID # : __________*Event # : __________ *Patient ID # : _____________ Social Security # : ___ ___ ___ - ___ ___ - ___ ___ ___ ___ Secondary ID # : _____________ Patient Name, Last: _________________ First: _____________ Middle: __________ *Gender: ___ F ___ M*Date of Birth: ____ / ____ / _______ Ethnicity (specify): ____________________Race (specify): __________________ *Event Type: _UTI_*Date of Event: ___ / ___ / _____ *Post-procedure UTI: ____Y ____N Date of Procedure: ____ / ____ / _______ NHSN Procedure Code: ________________ ICD-9-CM Procedure Code: ________________ *Location: ____________*Date Admitted to Facility: ___ / ___ / _____ MDRO Infection: ____ Y ____ N Risk Factors *Urinary catheter: ____Y ____ N Location of Device Insertion: ____________ Date of Device Insertion: ___ / ___ / _____ Event Details *UTI ____ Asymptomatic bacteriuria (ASB) – Specify criterion used: ____ Criterion 1____ Criterion 2 ____ Symptomatic UTI (SUTI) – Specify criterion used: ____ Criterion 1 ____ Criterion 2__(specify) ____ Criterion 3 ____ Criterion 4__(specify) ____ Other UTI (OUTI) – Specify criterion used: ____ Criterion 1 ____ Criterion 2 ____ Criterion 3__(specify) ____Criterion 4__(specify) *Secondary Bloodstream Infection: ____ Y ____ N **Died: ____Y ____ NUTI Contributed to Death: ____ Y ____ N Discharge Date: ____ / ____ / _______ *Pathogens Identified: ____ Y ____ NIf Yes, specify on reverse  Custom FieldsLabel_______________________ ____/____/___________________________ ____________________________________ ____________________________________ ____________________________________ ____________________________________ ____________________________________ _____________ Comments Assurance of Confidentiality: The information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). Public reporting burden of this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-79, Atlanta, GA 30333, ATTN: PRA ( ). CDC 57.75H (Front) Rev. 1, Effective date xx/xx/20xx Urinary Tract Infection (UTI) OMB No Exp. Date: xx-xx-20xx

UTI Pathogens: Select up to 3 organisms Pathogen # Gram-positive Organisms ______Coagulase-negativeVANC staphylococci (specify) ______________S I R N ______Enterococcus faecalisAMPDAPTOLNZPENGVANC S I R N S I R NS I R NS I R NS I R N ______EnterococcusAMPDAPTOLNZPENGQUIDALVANC faecium S I R N S I R N S I R NS I R N S I R NS I R N ______Staphylococcus CLIND DAPTO ERYTH GENT LNZ OX QUIDAL RIF TMZ VANC aureus S I R N S I R N S I R N S I R N S I R N S I R N S I R N S I R N S I R NS I R N Gram-negative Organisms ______Acinetobacter spp.AMKAMPSULCEFEPCEFTAZCIPROIMILEVOMEROPIPTAZ (specify) ______________ S I R N S I R NS I R N S I R NS I R N S I R NS I R N S I R NS I R N ______Escherichia coliAMKCEFEPCEFOTCEFTAZCEFTRXCIPROIMILEVOMERO S I R N S I R NS I R N S I R NS I R N S I R NS I R N S I R NS I R N ______Enterobacter spp.AMKCEFEPCEFOTCEFTAZCEFTRXCIPROIMILEVOMERO (specify) ______________ S I R N S I R NS I R N S I R NS I R N S I R NS I R N S I R NS I R N ______Klebsiella oxytocaAMKCEFEPCEFOTCEFTAZCEFTRXCIPROIMILEVOMERO S I R N S I R NS I R N S I R NS I R N S I R NS I R N S I R NS I R N ______Klebsiella pneumoniaeAMKCEFEPCEFOTCEFTAZCEFTRXCIPROIMILEVOMERO S I R N S I R NS I R N S I R NS I R N S I R NS I R N S I R NS I R N ______Serratia marcescensAMKCEFEPCEFOTCEFTAZCEFTRXCIPROIMILEVOMERO S I R N S I R NS I R N S I R NS I R N S I R NS I R N S I R NS I R N ______PseudomonasAMKCEFEP CEFTAZCIPROIMILEVOMEROPIP aeruginosa S I R N S I R N S I R NS I R N S I R NS I R N S I R NS I R N ______StenotrophomonasTMZ maltophilia S I R N Pathogen # Other Organisms Organism 1______________________________________________________ (specify)Drug 1Drug 2Drug 3Drug 4Drug 5Drug 6Drug 7Drug 8Drug 9 ____________________S I R N S I R NS I R N S I R NS I R NS I R N S I R NS I R NS I R N Organism 2______________________________________________________ (specify)Drug 1Drug 2Drug 3Drug 4Drug 5Drug 6Drug 7Drug 8Drug 9 ____________________S I R NS I R NS I R N S I R NS I R NS I R N S I R NS I R NS I R N Organism 3______________________________________________________ (specify)Drug 1Drug 2Drug 3Drug 4Drug 5Drug 6Drug 7Drug 8Drug 9 ____________________S I R NS I R NS I R N S I R NS I R NS I R N S I R NS I R NS I R N CDC 57.75H (Back) Rev. 1, Effective date xx/xx/20xx AMK = amikacin AMP = ampicillin AMPSUL = ampicillin/sulbactam CEFEP = cefepime CEFOT = cefotaxime CEFTAZ = ceftazidime CEFTRX = ceftriaxone CIPRO = ciprofloxacin CLIND = clindamycin DAPTO = daptomycin ERYTH = erythromycin GENT = gentamicin IMI = imipenem LEVO = levofloxacin LNZ = linezolid MERO = meropenem OX = oxacillin PENG = penicillin G PIP = piperacillin PIPTAZ = piperacillin / tazobactam QUIDAL = quinupristin / dalfopristin RIF = rifampin TMZ = trimethoprim / sulfamethoxazole VANC = vancomycin Result codes: S = susceptible I = intermediate R = resistant N = not tested